Irene Flores' advocacy for bedside nurses helped build a local stem cell transplant program, making her an Extraordinary Healer Award nominee.
|Articles|September 1, 2021
Episode 10 The Pluses and Minuses of Cystoscopies, TURBT and Other Diagnostic Tools with Dr. Alexander Kutikov
Host Rick Bangs’s special guest is Dr. Alexander Kutikov, MD, FACS of Fox Chase Cancer Center in Philadelphia.
Advertisement
In Episode 10 of
Rick and Dr. Kutikov discuss:
- What can a
cystoscopy tell you about the bladder cancer stage? - Is a
blue light cystoscopy better than a white light? - What about x-rays and CT scans? Can they give you different information than a cystoscopy?
Dr. Alexander Kutikov
Never miss an episode by subscribing to Bladder Cancer Matters on your favorite podcast platform like
Link to page:
Advertisement
Related to this article
Lunsumio added to Revlimid kept relapsed or refractory follicular lymphoma from worsening longer than Rituxan plus Revlimid in the phase 3 CELESTIMO trial.
Three new studies from WCLC 2026 show strong results in ROS1-positive NSCLC, EGFR-mutant NSCLC and relapsed small cell lung cancer, offering fresh options.
See 5 years of FDA leukemia approvals for CLL, AML and CML — new drugs, new drug classes, and how many patients they've actually helped.
Phase 2 findings on divesiran point to a potential way to control hematocrit while reducing repeated blood draws for those living with polycythemia vera, like Nona Baker.
Four of seven patients had no visible cancer on scans in early data from CONVERGE, a trial testing a tumor injection meant to boost radiation in lung cancer.
FDA approves Inluriyo plus Verzenio for adults with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.
September is Blood Cancer Awareness Month, and the pipeline for leukemia, lymphoma and myeloma is as active as it has been in years.
Advertisement
Advertisement